| CPC A61N 5/0622 (2013.01) [C09K 11/565 (2013.01); C09K 11/65 (2013.01); C09K 11/883 (2013.01); A61N 2005/0631 (2013.01); A61N 2005/0645 (2013.01); A61N 2005/0661 (2013.01); A61N 2005/0663 (2013.01); B82Y 5/00 (2013.01); B82Y 20/00 (2013.01)] | 17 Claims |
|
1. Therapeutic device to be applied to the skin in correspondence with the primary and secondary nerve endings of tendons, muscles, dermatomes and nerve endings, whose painful and inflammatory neuro-muscular and postural remodulation is to be favoured, including at least one laminar support element (1), and a mixture given by the combination of at least two types of quantum dots, including the following: (2)
Graphene quantum dots Code 900708 or quantum dots with a fluorescence indicatively corresponding to: λex 350 nm; λem 445 nm, FWHM 65 nm, quantum yield >65%;
Graphene quantum dots blue luminescent Code 900726 or quantum dots with a fluorescence approximately corresponding to: λex 350 nm; λem 445 nm±10 nm, FWHM 75 nm, quantum yield ≥20%
Graphene quantum dots cyan luminescent, Code 900707 or quantum dots with a fluorescence indicatively corresponding to: λem 475-495 nm, FWHM 70 nm, quantum yield >17%
Graphene quantum dots aqua green luminescent, Code 900712 or quantum dots with a fluorescence indicatively corresponding to: λex 485 nm; λem 530 nm±10 nm, FWHM 80 nm, quantum yield ≥17%;
Perovskite quantum dots oleic acid and oleylamine coated, Code 900747 or quantum dots with a fluorescence indicatively corresponding to: λem 480 nm;
CdTe core-type quantum dots COOH functionalized Code 777978 or quantum dots showing a fluorescence indicatively corresponding to: λem 710 nm, quantum yield ≥15%;
CdS/ZnS core-shell type quantum dots oleic acid functionalised Code 900286 or quantum dots showing a fluorescence indicatively corresponding to: λmax 385 nm λem 400 nm±10 nm, quantum yield >50%;
CdS/ZnS core-shell type quantum dots oleic acid functionalised Code 900283 or quantum dots showing a fluorescence indicatively corresponding to:
λmax 405 nm λem 425 nm±10 nm;
where said support consists of a laminar element of transparent material at the reference wavelengths and at the wavelength of radiation emitted by the human body, a first side of the laminar support (1) can be put in contact with the skin of the person whose dysfunction or inflammatory pathology is to be treated, and being placed on the opposite side of the first side of said support (1), or incorporated or diffused in the laminar element itself, a mixture of at least two of said quantum dots (2), with a concentration of 1 mg/cm2 to 100 mg/cm2, capable of emitting photons in the reference wavelength, with an intensity of between 0.1 mW/cm2 and 0.5 mW/cm2, and preferably between 0.2 mW/m2 and 0.4 mW/cm2, and the reference wavelength being between 280 nm and 740 nm, and preferably between 350 nm and 530 nm, when stimulated by at least one electromagnetic radiation infrared, luminous or ultraviolet tics.
|